Rituximab administration for chronic antibody-mediated rejection after kidney transplantation

Rituximab administration for chronic antibody-mediated rejection after kidney transplantation - Rituximab administration for chronic antibody-mediated rejection after kidney transplantation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018567

Enrollment

Registered

2015-08-14

Start date

2015-08-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antibody-mediated rejection after kidney transplantation

Interventions

Rituximab administration Rituximab 375 mg/m2 (maxium dose 500mg)/week x 2 dose

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patient who suffer from antibody-mediated rejection after kidney transplantation

Exclusion criteria

Exclusion criteria: The patient who is judged by the patient's physician as unsuitable for participation in the study

Design outcomes

Primary

Measure	Time frame
Change in renal function at 6 months	—

Countries

Japan

Contacts

Public ContactAkihiko Matsuda

Saitama Medical Center, Saitama Medical University Department of Nephrology and Hypertension

akihikom@saitama-med.ac.jp049-228-3604

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026